

CORPORATE BROCHURE


**Transforming patient outcomes
through life-changing science
and innovation**



Galapagos

WE ARE GALAPAGOS

Operations in the U.S. and Europe



FOCUS ON ONCOLOGY AND IMMUNOLOGY

- High unmet needs indications with breakthrough designation potential
- Biologically validated targets and best-in-class medicines

UNIQUE TECHNOLOGIES DRIVING PIPELINE GROWTH

- Fully-integrated end-to-end small molecule R&D capabilities
- Decentralized cell therapy manufacturing platform and biologics-based discovery engine

ROBUST AND GROWING R&D PIPELINE

- >20 small molecule and cell therapy programs
- 4 assets in multiple clinical studies
- From 2026, aim to initiate ≥ 2 clinical programs per year

STRONG FINANCIAL POSITION

- €3.4 Bn in cash and current financial investments as of June 30, 2024
- To invest internally and for strategic business development

A STORY OF CHANGE TO ENSURE A SUSTAINABLE FUTURE

In just two years, Galapagos has undergone a profound transformation, establishing a strong foundation for long-term value creation. Our journey began with a strategic pivot to transform Galapagos into a pioneering biotech company, expanding into life-changing cell therapies in oncology, beyond our existing expertise in small molecules and immunology.

“ Our journey began with a strategic pivot to transform Galapagos into a **pioneering biotech company**, expanding into life-changing cell therapies in oncology.

Recognizing the need for agility and focus, we redefined our R&D approach to be more patient-centric, focusing on what matters most to patients and their physicians. By focusing on two therapeutic areas and on biologically validated targets, we have de-risked our R&D efforts and accelerated innovation. This shift has allowed us to collaborate more effectively, both internally and externally, ensuring that we concentrate our resources on developing medicines for high unmet medical needs. As a result, we have initiated over 15 new research projects, each with the potential to deliver transformational medicines. In addition, five clinical studies are currently ongoing, and from 2026 onwards, we aim to have two candidates entering our clinical pipeline annually.

We have moved at pace to forge important strategic partnerships, license agreements, R&D collaborations, acquisitions, and equity investments. The transfer of the Jyseleca® business, to refocus on innovation and growth, marked the final step in our transformation into a pure-play biotech company. With the transfer, we streamlined our organization, reducing our workforce from 1,200 to 650 FTEs and significantly cutting our cash burn, ensuring a lean and efficient operation.



Together, these changes have strengthened our strategic position and set us on a clear path toward sustainable growth and long-term success. With differentiated, established technology platforms, deep R&D expertise, a strong balance sheet and a highly experienced leadership team, Galapagos is well-equipped to continue its mission of delivering valuable life-changing therapies to patients worldwide.

“

By focusing on two therapeutic areas and on biologically validated targets, we have de-risked our R&D efforts and accelerated innovation.



OUR VISION

TRANSFORMING PATIENT LIVES THROUGH INNOVATION

In a world where remarkable advances in oncology and immunology have been made, there remains a significant need for patients with hard-to-treat diseases to have improved and broader access to innovative therapeutic options. At Galapagos, we are united by our purpose to transform patient outcomes for more years of life and better quality of life across the globe.

OUR MISSION

ACCELERATING BREAKTHROUGHS
WITH RELENTLESS PURSUIT

Our mission is clear and ambitious - to accelerate transformational innovation by relentlessly pursuing groundbreaking science with an entrepreneurial spirit and a collaborative mindset. We believe in pushing the boundaries of what is possible, not just for the sake of innovation, but to make a real, tangible difference in the lives of patients.



STRATEGIC FOCUS

LEADING WITH
PURPOSE

Our strategic focus is built around addressing high unmet needs and developing medicines with breakthrough potential in oncology and immunology. We aim to leverage biologically validated therapeutic targets to deliver best-in-class medicines, combining unique technologies with drug development expertise across different modalities. This approach enables us to drive our pipeline forward, offering cutting-edge cell therapies and small-molecule precision medicines. Our commitment to focused and selective value-enriching deals helps broaden our portfolio and strengthen our capabilities, ensuring that we are always at the forefront of medical innovation.


“ At Galapagos, we are united by our purpose to transform patient outcomes for **more years of life and better quality of life** across the globe.

REASONS TO BELIEVE

STRONG FUNDAMENTALS FOR LONG-TERM VALUE CREATION

Galapagos is a different kind of biotech company. We are a pure-play, innovative leader with differentiated, established technology platforms, R&D expertise from early discovery to clinical development, and the financial strength to invest strategically for the long term. Our extraordinary team works across multiple sites in Europe and the U.S., bringing together a diverse group of talented professionals who are passionate about transforming patients' lives. Our team is headed by renowned life sciences leaders who, between them, have brought over 30 medicines to market. This proven expertise, together with our strategic focus and ambitious culture drives our commitment to creating impact for patients and value for shareholders.

“ Our strategic focus is built around **addressing high unmet needs** and developing medicines with breakthrough potential in oncology and immunology.



FUTURE AMBITION

BRINGING TRANSFORMATIONAL MEDICINES TO ALL

We are committed to executing our strategic roadmap to bring transformational medicines to the broadest patient population possible. Our goal is not just to meet current medical needs but to anticipate and shape the future of healthcare, ensuring that our innovations reach those who need them most.

OUR VALUES

OUR CORE BELIEFS DRIVE OUR ACTIONS

At Galapagos, our values are the principles that guide us and shape every decision we make:



We put patients first, always.

Our commitment to patients is unwavering. Their needs are at the heart of everything we do.



We innovate with open minds.

We embrace new ideas and challenges with an open and creative approach, continuously seeking better ways to solve the toughest problems in healthcare.



We take ownership.

We hold ourselves accountable to the highest standards, taking responsibility for our actions and outcomes.



Together, we make-it-happen.

Collaboration is the cornerstone of our success. By working together, we achieve more.



“ At Galapagos we pioneer for patients. Their needs are at the heart of everything we do.

FORWARD, FASTER
FOR ALL OUR STAKEHOLDERS

Galapagos is more than a company. It is a purpose-driven force for change in the world of biotech. With a clear vision, strategic focus, and a deep commitment to our core values, we are dedicated to transforming lives and pioneering the future of medicine. Supported by our extraordinary team across Europe and the U.S., we are not just envisioning a better future—we are building it, one breakthrough at a time.



“ We look forward with great optimism to a sustainable future as we continue to innovate for patients to give them what matters most: **more time with family and friends. More joy. Longer, healthier, better-quality lives.** ”



Galápagos



Galápagos

www.glpq.com

2024 © Galapagos NV